Abdurrahmaan Ali Suei Elbuzidi: What is the Optimal Anticoagulation Monitoring Target in ECMO?
Abdurrahmaan Ali Suei Elbuzidi, ECMO and Critical Care Consultant at Hamad Medical Corporation, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Journal of Cardiothoracic and Vascular Anesthesia, adding:
“Excited to share that our latest systematic review and meta-analysis has been published:
‘Clinical Outcomes of Different Heparin Anticoagulation Monitoring Targets in Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis.’
This work explores an important and ongoing challenge in ECMO care:
What is the optimal anticoagulation monitoring target?
Despite widespread use of unfractionated heparin in ECMO, significant variability remains in monitoring strategies (ACT, aPTT, anti-Xa, and others), with potential implications for bleeding, thrombosis, and overall patient outcomes.
Our review aimed to synthesize the available evidence and evaluate how different monitoring targets may influence clinical outcomes.
Proud to have collaborated with an outstanding multidisciplinary team of colleagues on this project.Special thanks to all co-authors for their dedication and contributions.
Looking forward to continued research that helps refine anticoagulation strategies and improve outcomes for ECMO patients.”
Title: Clinical Outcomes of Different Heparin Anticoagulation Monitoring Targets in Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-analysis
Authors: Alaa Rahhal, Ans Alamami, Rabee Tawel, Ahmed Shebani, Hassan Fahed El Daezli, Abdurrahmaan Elbuzidi, Nadir Kharma, Amr Omar, Ahmed Labib Shehatta
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 5, 2026, 15:31Irma Bagdoniene: Multidisciplinary Management of High-Risk Familial Hypercholesterolaemia and CAD
-
Oct 5, 2026, 15:00Serena Williams and Pulmonary Embolism: From Personal Crisis to Lessons in Venous Thromboembolism
-
Oct 5, 2026, 14:55Marco Moscarelli: 3D Reconstruction Enhances Volumetric Assessment of Post-TAVI Thrombosis
-
Oct 5, 2026, 13:24Abdul Muqtadir Abbasi: Diagnostic Pearls for Evaluating Isolated Thrombocytopenia in Residents
-
Oct 5, 2026, 13:16Katerina Pavenski: Rethinking What ‘Normal’ Means for Iron Deficiency
-
Oct 5, 2026, 13:09Rick Matthews: Balancing Established VTE Partnerships with Innovative Interventional Technologies
-
Oct 5, 2026, 13:01Nawsherwan Mohammad: Recognizing TTP Before the ADAMTS13 Result Arrives
-
Oct 5, 2026, 12:51Bruno Pougault: The Hidden Challenges Behind Anti Xa Testing
-
Oct 5, 2026, 12:41Syed Huzaifa Khan: Rethinking CTRP12 as a Biomarker for In Stent Restenosis